Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-PDAC-288 first-line metastatic pancreatic ductal adenocarcinoma study
jRCT2031260004Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing Telisotuzumab adizutecan + FOLFOX with Standard of care (2 arms). Primary endpoints: Overall response and Overall survival. Started Apr 2026; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031260004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260004.